Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse

Human Gene Therapy

Volumn 5, Issue 3, 1994, Pages 381-397

  Heslop, Helen E ^a   Brenner, Malcolm K ^a   Rooney, Cliona ^b   Krance, Robert A ^b   Roberts, W Mark ^b   Rochester, Richard ^b   Smith, Colton A ^b   Turner, Victoria ^b   Sixbey, John ^c   Moen, Robert ^d   Boyett, James M ^e  

^a Division of Bone Marrow Transplantation ^*  (United Kingdom)

^b Department of Virology and Molecular Biology ^*  (United Kingdom)

^c Department of Hematology/Oncology ^*  (United States)

^d Departments of Virology and Molecular Biology and Infectious Diseases ^*  (United Kingdom)

^e Genetic Therapy Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPSTEIN BARR VIRUS; GENE THERAPY; GENETIC TRANSDUCTION; HLA MATCHING; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MARKER GENE; NONHUMAN; PHENOTYPE;

ADULT; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CELL LINE; CHILD; CLINICAL PROTOCOLS; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE; FEMALE; GENETIC VECTORS; GRAFT VS HOST DISEASE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMAN; IMMUNOCOMPROMISED HOST; INCIDENCE; INFORMED CONSENT; KANAMYCIN KINASE; LEUKEMIA; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MALE; MOLONEY MURINE LEUKEMIA VIRUS; MYELODYSPLASTIC SYNDROMES; NEOMYCIN; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECOMBINANT FUSION PROTEINS; SAFETY; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR VIRUS INFECTIONS; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4;

EID: 0028066696     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.1994.5.3-381     Document Type: Article

References (31)

1. Anasetti C, Amos D, Beally PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O'Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA. Effect of HLA compatibility of engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320: 197-204, 1989.
2. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Floumoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA. Marrow transplantation from related donors other than HLA-identical siblings. N Engl. J Med 313: 765-771, 1985.
3. Gajewski, Cecka M, Champlin R. Bone marrow transplantation utilizing HLA-matched unrelated marrow donors. Blood Rev 4: 132-138, 1990.
4. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Tmitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, GoUschall JL, Oldham K, Anderson T, Camitta B, Menitove J. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 322: 485-494, 1990.
5. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation; Results in 102 cases. Blood 75: 1728-1732, 1990.
6. MacKinnon S, Hows JM, Goldman JM, Arthur CK, Hughes T, Apperiey JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Gallon DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H. Bone marrow tran,splantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors. Exp Hematol 18: 421-425, 1990.
7. Soiffer RJ, Mauch P, Tarbell NJ, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Murrey CI, Coral F, Bosserman L, Dear K, Nadler LM, Ritz J. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 7: 23-33, 1991.
8. Marks DI, Cullis JO, Ward K, Goldman J.M. Increased incidence of viral infections in volunteer unrelated donor (VUD) bone marrow transplants compared to sibling donor (SD) transplants for chronic myeloid leukemia (CML). Blood 10 (Suppl 1) 1992.
9. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA and the City of Hope-Stanford-Syntex CMV Study Group. A randomized, controlled trial of prophylactic Ganciclovir for cytomegaloviras pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324: 1005-1011, 1991.
10. Goodrich JM, Mori M, Cleaves CA, DuMond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. Early treatment with Ganciclovir to prevent Cytomegaloviras disease after allogeneic bone marrow transplantation. N Engl J Med 325: 1601-1607, 1991.
11. Miller, G. Epstein-Barr Viras. Biology, pathogenesis and medical aspects. In: Virology, edited by Fields, B.N. and Knipe, DM. New York: Raven Press Ltd, p 1921-1958, 1990.
12. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL: Epstein-Barr viras, immunodeficiency, and B cell lymphoproliferation. Transplantation 39: 461-472, 1985.
13. Tricot G, Hedderman A, Leemhuis T, Hilton J, Baute J, Broun R, Hromas R, Hoffman R, Cometta K, Okarma T, Lebkowski J, Srour EF. Unrelated allogeneic bone mairow transplantation (BMT) using T-cell depletion with soybean agglutination and the cellector™ CD5/CD8 or E rosetting. Exp Hematol 20: 719, 1992.
14. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Dumam DM: Epstein-Barr viras lymphoproliferation after bone marrow fransplantation. Blood 72: 520-529, 1988.
15. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH: Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71: 1234-1243, 1988.
16. Gratama JW, Zutter MM, Minarovits J, Oosterveer MAP, Thomas ED, Klein G, Emberg I. Expression of Epstein-Barr viras-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 47: 188-192, 1991.
17. List AF, Greco A, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein Barr viras. J Clin Oncol 5: 1673-1689, 1987.
18. Fischer A, Blanche S, LeBidois J, Bordigoni P, Gamier JL, Neaudet P, Morinet F, Le Deist F, Fischer A-M, Griscelli C, Him M: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324: 1451-1456, 1991.
19. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr viras (EBV): Implications for the immune confrol of EBV-positive malignancies. J Exp Med 176: 157-168, 1992.
20. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localization of Epstein-Barr viras cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176: 169-176, 1992.
21. Harrington DS, Weisenburger DD, Purtilo DT. Malignant lymphoma in the X-Iinked lymphoproliferative syndrome. Cancer 59: 1419-1429, 1987.
22. Reittie JE, Gottlieb DJ, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK. Endogenously activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73: 1351-1358, 1989.
23. Heslop HE, Gottlieb DJ, Reittie JE, Bello-Femandez C, Meager A, Prentice HG, Brenner MK. Spontaneous and Interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol 72: 122-126, 1989.
24. Rencher SD, Hanif I, Heslop HE, Tumer V, Brenner MK, Hurwitz JL. Reconstitution of the T-cell receptor aP repertoire in recipients of allogeneic bone marrow transplant. Bone Marrow Transplant 10: 521-527, 1992.
25. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241, 1992.
26. Brenner M, Mirro J, Jr., Hurwitz C, Santana V, Ihle J, Krance R, Ribeiro R, Roberts WM, Mahmoud H, Schell M, Garth K: Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther 2: 137-159, 1991.
27. Santana VM, Brenner MK, Ihle J, Krance R, Furman W, Bowman L, Ribeiro R, Hurwitz C, Mahmoud H, Moen RC, Anderson WF: A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Therap 3: 257-272, 1991.
28. Santana VM, Brenner MK, Ihle J, Krance R, Furman W, Bowman L, Ribeiro R, Hurwitz C, Mahmoud H, Moen RC, Anderson WF: A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther 2: 273-286, 1991.
29. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN. Gene marked cells in remission marrow can contribute to relapse after autologous bone marrow transplantation. Lancet 341: 85-86, 1993.
30. Brenner MK, Rill DR, Holladay M, Heslop HE, Buschle M, Moen RC, Krance RA, Anderson WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores long term hemopoiesis in cancer patients. Lancet 342: 1134-1137, 1993.
31. Rosenberg SA, Aebersold P, Cometta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF. Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-inflltrating lymphocytes modified by refroviral gene transduction. N Engl J Med 323: 570-578, 1991.